knowledge -WSS

knowledge

author：fashion 2025-09-29 01:39:24 - browse：7748

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： FDA weighs limits of animal data in assessing artificial wombs

WSS

Congress: Eradicate hepatitis C and reduce the deficit

Federal judge rules Oregon’s tough new gun law is constitutional

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Congress likely to miss an opportunity to fix drug shortages issue

entertainment

knowledge

explore

How to save PrEP access — and even expand it

The unintended consequences of overturning Roe v. Wade

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Senate bill would ban some hospital facility fees

As demand for Covid shots wanes, Moderna seeks its next success

Grad students accuse University of California of wage theft

Alkermes shareholders re

Who gets to use the title 'doctor'?

Dobbs anniversary: the lost opportunity of abortion as health care

Can CDC director Mandy Cohen drive consensus in Washington?

explore

The new HIV moral panic

Why the quest to eradicate polio has stumbled

PBMs drew scrutiny in House hearing — and so did pharma

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Blood tests recalled over risk of missed heart attack diagnosis

Grail faces three suits alleging harassment, retaliation

focus

focus

knowledge

explore